Top Tweets for #mtnBC
“The ASCENT trial was a real eye-opener.” — Dr. Joyce O’Shaughnessy
In this discussion, Dr. O’Shaughnessy (@BCJoyceO) reflects on the landmark ASCENT trial and why the survival benefit seen with SG represented such a meaningful advance for patients with metastatic triple-negative breast cancer.
Hear her perspective on the data and its impact on clinical practice by watching the full conversation at https://t.co/xzGBBholqu
Change in oncology is often slow, but I’ve witnessed real & meaningful progress since my #mTNBC dx in 2016.
The conversation around #ctDNA is evolving quickly. Many patients are requesting testing, many oncologists are already using it, & ctDNA is becoming increasingly integrated into #clinicaltrials. We still need more data & consensus on clinical utility, but because these decisions are already happening in clinics every day, patients & oncologists also need clear guidance while that evidence continues to evolve.
And now we’re adding another important ❓ to the discussion: molecular vs radiographic progression. What should it mean, when should it influence tx decisions? Most patients understand that the evidence is still evolving, making shared decision-making even more important.
A good read 👇🏻
#bcsm
#Serena6
#metastaticbreastcancer
As the debate surrounding SERENA-6 data continues, breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer @breastoncdoc @stolaney1 #bcsm #oncology https://t.co/BgvNS6WzVK
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
https://t.co/KT5gQIBrPI
Learn more 👉 https://t.co/aBf3F81wPI
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #TNBC #BreastCancer #BCSM | @JavierCortesMD | @stolaney1 | @PTarantinoMD | @E_de_Azambuja | @ElisaAgostinett
As I approach my 10-year #mTNBC metaversary 6/29, I’m reflecting on one truth: time is not distributed equally in the #metastaticbreastcancer community.
My friend Abigail’s (@AMJohnston1315) latest blog beautifully captures the reality of living with MBC: the treatments, scans, uncertainty, side effects, endurance, love, loss, & anticipatory grief that never fully leaves.
Some days, the weight of that grief feels unbearable ❤️🩹But, it’s impossible to walk away from a community filled with people whose courage, wisdom & friendship mean more to me than words can express.
Cancer offers no gifts. It steals futures, health, time, & lives. But through this dx, I’ve been privileged to know extraordinary people whose friendship has forever changed me.
To my friends living with MBC: thank you. It’s a privilege to walk alongside you. I’ll continue to honor your stories, your contributions, & your impact for as long as I am able.
Take a few minutes to read Abigail’s essay, it’s both heartwarming & 💔
#bcsm
New blog post up — my Nine year Metaversary … https://t.co/1Snyy4bp9i #bcsm
📢Today - June 9th at 3:00 PM EST!
#MBC Impact Series, hosted by @SusanGKomen, on Metastatic Triple Negative Breast Cancer.
Register to hear from @DanaFarber's Dr. Ana Garrido-Castro as she speaks on the current treatments and recent research for #mTNBC.
https://t.co/7ijaEmXKi8
📢 @ASCO : Frontline sacituzumab govitecan + pembrolizumab delivered durable benefit in PD-L1+ #mTNBC, improving PFS2 by 33% vs chemo + pembrolizumab—even with ~80% crossover to sacituzumab govitecan. @KalinskyKevin @WinshipAtEmory
The findings further support use of the combination in this population.
Read more: https://t.co/zsFMG4pfgE
#ASCO26 Abstracts 1001 and 1002.
Both follow up on trials that already changed frontline #mTNBC in 2025.
#ASCENT03 (Abstract 1001): #sacituzumab_govitecan established at ASCO 2025. Now, does the PFS benefit hold beyond first progression? PFS2 18.2 vs 14.0 months. HR 0.70.
>Yes! even with 82% crossover to SG in the chemo arm.
#TROPION_Breast02 (Abstract 1002): #datopotamab_deruxtecan established at #ESMO2025. Same indication. Now>same question. PFS2 15.6 vs 11.8 months. TFST 10.9 vs 5.6 months.
>Yes! and the benefit starts at first-line and carries forward.
Both TROP2. Both TOP1 inhibitors. SN-38 vs DXd-different molecules, different linkers, different toxicity profiles.
Both category 1 NCCN 2026. No head-to-head. No sequencing trial.
Prior TOP1 ADC exposure collapses the next one regardless of antibody. 52 days vs 455.
Two standards.
One open question.
#bcsm #TNBC
RT to all metastatic lesions wasn’t part of my original tx plan, but after a CR to 1L AC chemo in 2017, my oncologist shifted gears & pursued an aggressive approach for my oligo recurrent #mTNBC. Initially not framed as curative, his thinking changed after my exceptional response to systemic therapy. Is that part of why I’m nearing 10 years since #mTNBC dx & 9+ years NED as a 🦄? Who knows?
TROPION-Breast02:
Dato-DXd redefines 1L mTNBC beyond efficacy alone.
A near 3-fold prolongation in QoL preservation vs chemotherapy (TTD 23.5 vs 8.3 mo; HR 0.64) signals a paradigm shift toward "quality survival"
#ESMOBreast26 @OncoAlert #mTNBC #ADCs #bcsm
Check out this @Nature paper 👉 A glucocorticoid-FAS axis controls immune evasion during metastatic seeding.
👉https://t.co/ZqiQjqaN0J
@debog93 @PBaldominos @laken66174680 @elmayermd @CellDeathLab @EMittendorfMD @JudithAgudo1 @HSCRB #BreastCancer #TNBC
ADCs are Now Listed as a 1L Option in mTNBC - Abirami Sivapiragasam
@AbiSivaMD @PTarantinoMD @RitaNandaMD
https://t.co/ewVjDlPFZ8
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #mTNBC #BreastCancer #ADCs
I absolutely love this!!! new NCCN guidelines: ADCs are now listed as a first-line option in mTNBC, even before FDA approval.
#NCCN #NCCNGuidelines
#BreastCancer
#mTNBC
#OncologyUpdates
#ClinicalPractice
📌Another must-read from Abigail!
As another 🙋♀️dx w/ a 2nd primary cancer (MMIS), this resonates. However, unlike Abigail ~ I’ve no personal exp w/ progression of disease after a CR to 1L tx for #mTNBC, OR ongoing tx-related SEs. Such heavy lifts she carries so well while advocating for & supporting others w/ #MBC.
#bcsm
Doors and windows and a new primary cancer … https://t.co/KQx1K4G2Oh #bcsm
#bcsm❗️If you’re living w/ #metastaticbreastcancer & interested in advocacy, I highly recommend Living Beyond Breast Cancer’s Hear My Voice (HMV) training. It’s where my advocacy began in 2017, less than 1 yr after my stage IV #mTNBC diagnosis, introduced me to a community I didn’t know existed, people who became close friends, & opened doors I never imagined.
Deadline: 1/28/26
Apply 👉🏻 https://t.co/eitif39Leq
♥️ this, thank you for sharing. Looking back can offer hope & perspective - seeing what’s changed in 10 yrs. 2025 ACS 5 yr survival is ~30% vs 22% in 2016, small but meaningful progress. As an #mTNBC exceptional responder & outlier, I see potential, but being a 🦄 is lonely after losing so many friends since my 2016 dx, while holding hope for what might be possible.
And still so little progress for #mTNBC 😕 - where hope can be elusive. Grateful for @stolaney1’s presentation w/ studies on new/novel drug targets/payloads: ADCs (B7H9 - Emi-Le (XMT-1660), Bispecific (EGFR & HER3, Izalontomab brengitecan), & Peptide conjugate (Nectin 4, tubulin inhibitor) - 🤞🏻🤞🏻
✅ Clear PFS benefit with 1L sacituzumab govitecan in IO-ineligible mTNBC
⚖️ OS neutral — explained by 82% crossover & immature data
📊 Evidence matters. Context matters more.
#ASCENT03 #NEJM #mTNBC #BreastCancer #Oncology #ClinicalTrials
Our real-world study on sacituzumab govitecan in mTNBC has been published in the International Journal of Cancer.
✅Median PFS: 5.4 months
✅Median OS: 12.2 months
✅ORR: 36.8% | DCR: 63.9%
✅Safety profile consistent with clinical trials
#SacituzumabGovitecan #mTNBC #BreastCancer #Oncology #RealWorldEvidence @OncoAlert @SalihTunbekici @Larvol
Dr. Sara Tolaney (@stolaney1) will discuss the emerging role of #ADCs in first line metastatic #TNBC at #ESMO25.
🗓️Saturday, October 18
⏰ 13 – 14:30 CEST (7 – 8:30 AM EST)
📍 Koblenz Auditorium Hall 5.2
#BreastCancer #mTNBC #TripleNegativeBreastCancer
5 palliative radiotherapy sessions complete. Another week gone in hospital trips and nurse appointments. #mtnbc #sbc really is a gift for life that you don't want. Thought I deserved a treat for still existing!
#Stage4DeservesMore
@METUPUKorg
@Make2ndsCount
Last Seen Hashtags on Sotwe
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.4M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.8M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.1M followers
Taylor Swift
@taylorswift13
81.9M followers
Lady Gaga
@ladygaga
73.4M followers
Virat Kohli
@imvkohli
70.5M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.1M followers
Neymar Jr
@neymarjr
63.4M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
Selena Gomez
@selenagomez
61.1M followers
X
@x
60.8M followers